Fate Therapeutics upgraded by BofA Securities
$FATE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BofA Securities upgraded Fate Therapeutics from Underperform to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/18/2024 | Underperform → Neutral | BofA Securities | |
| 6/17/2024 | $4.00 → $6.00 | Neutral → Overweight | Piper Sandler |
| 3/27/2023 | $6.00 | Equal Weight | Wells Fargo |
| 1/24/2023 | $115.00 → $7.00 | Buy → Neutral | H.C. Wainwright |
| 1/6/2023 | $20.00 → $7.00 | Outperform → Market Perform | BMO Capital Markets |
| 1/6/2023 | $71.00 → $12.00 | Overweight → Neutral | Piper Sandler |
| 1/6/2023 | Outperform → Market Perform | Cowen | |
| 1/6/2023 | $107.00 → $5.30 | Buy → Hold | Stifel |
BofA Securities upgraded Fate Therapeutics from Underperform to Neutral
Piper Sandler upgraded Fate Therapeutics from Neutral to Overweight and set a new price target of $6.00 from $4.00 previously
Wells Fargo resumed coverage of Fate Therapeutics with a rating of Equal Weight and set a new price target of $6.00
All three patients treated with FT819 following fludarabine-free conditioning regimen for severe lupus nephritis achieve Primary Efficacy Renal Response (PERR); first patient to reach 1-year follow-up continues in drug-free Definition of Remission in SLE (DORIS) First extrarenal SLE patient on maintenance therapy treated with FT819 in the absence of conditioning achieves Low Lupus Disease Activity State (LLDAS) at 3-month follow-up and maintained at 6 months Cumulative clinical experience in nearly 60 patients treated with off-the-shelf program across autoimmunity and oncology continues to support therapeutic differentiation with favorable safety profile and short duration of hospitalizati
SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Matthew Abernethy, M.B.A., to its Board of Directors effective as of May 29, 2025. Mr. Abernethy brings to the Company over 15 years' experience in corporate finance and investor relations in the biotech and medical device industry. In addition, the Company announced that Timothy P. Coughlin stepped down from the Board of Directors, effective concurrently with Mr. Abernethy's appointment. "Mr. Aberne
SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced that clinical and preclinical data from the Company's off-the-shelf cell therapy product platform will be featured at the European Alliance of Associations for Rheumatology European Congress of Rheumatology (EULAR 2025), being held in Barcelona, Spain on June 11-14, 2025. The Company has been selected to provide an oral presentation featuring clinical data from its ongoing Phase 1 clinical trial of FT819